> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Bispecific Antibody Development Programs
- URL: https://www.fdaweb.com/guide-on-bispecific-antibody-development-programs-2/
- Published: 2019-04-19T12:00:00.000Z
- Updated: 2026-09-15T01:21:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143913

*Federal Register* notice: FDA has made available a draft guidance entitled “Bispecific Antibody Development Programs.” The document covers general considerations and recommendations for these programs, as well as regulatory, quality, nonclinical, and clinical considerations in the context of bispecific antibody development programs. It does not discuss development considerations for other multitarget therapies that are combinations of monoclonal antibodies or are antibody cocktails or polyclonal antibodies. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-04-19/pdf/2019-07930.pdf?ref=fdaweb.com).